Video

The Armada Summit and NASP

National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the significance of the annual Armada Specialty Pharmacy Summit.

National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the significance of the annual Armada Specialty Pharmacy Summit.

This video was recorded courtesy of Armada Health Care at the 2015 Armada Specialty Pharmacy Summit in Las Vegas, Nevada.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com
Related Content
FDA Approved Food and Drug Administration concept. Person with FDA icon on virtual screen for Health product standards control system.
June 30th 2025

FDA Approves Emapalumab-Lzsg as First-Ever Treatment for Macrophage Activation Syndrome in Still Disease

Luke Halpern, Assistant Editor
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
March 31st 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
Creative layout of colorful pills and capsules on blue background. Minimal medical concept. Pharmaceutical, Covid-19 or Coronavirus. Flat lay, top view
June 26th 2025

Mid-Year Roundup: FDA’s Novel Retail and Specialty Drug Approvals in 2025

Luke Halpern, Assistant Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
Pediatric multisystem inflammatory syndrome. kawasaki disease symptoms.
June 23rd 2025

IVIG-Glucocorticoid Combination Therapy Reduces Need for Adjunctive Immunotherapy in Pediatric MIS-C

Luke Halpern, Assistant Editor
FDA Approves Dupilumab for Treatment of Bullous Pemphigoid
June 20th 2025

FDA Approves Dupilumab for Treatment of Bullous Pemphigoid

Aislinn Antrim, Managing Editor